P

PSI CRO

Global CRO delivering on-time patient enrollment

Business Development Representative - Clinical Trials

Full-Time
No salary listed
Mid
Bachelor's
United States
HybridHybrid work with site visits required.
Sales & Account Management

About the job

Requirements
  • A college or university degree in a life science or other medical-related field.
  • ICH Good Clinical Practice training.
  • At least 3 years of experience within the clinical research industry.
  • At least 2 years of experience working with sponsors, biopharma partners, and contract research organizations in the clinical research industry.
  • Previous experience in business development, site relationship management, or stakeholder engagement within the clinical research industry.
  • Strong understanding of clinical trial processes, site operations, and sponsor and contract research organization collaboration models.
  • Experience developing and maintaining long-term professional relationships with industry stakeholders.
  • Proven ability to identify growth opportunities and support partnership development.
  • Fluency in English.
  • Proficiency in Microsoft Office Suite, including Excel, Word, PowerPoint, and Outlook, and internet research tools.
  • A valid Category B driver's license.
Responsibilities
  • Identify potential medical institutions that meet the collaboration criteria.
  • Initiate outreach to medical institutions to explore collaboration interest, build early engagement, and qualify interest.
  • Conduct introductory meetings with prospective medical institutions to assess research capabilities, infrastructure, and areas of interest.
  • Coordinate documentation and information required to evaluate medical institutions for potential collaboration.
  • Build and maintain relationships with sponsors, contract research organizations, biopharma partners, and medical institutions to support business development activities.
  • Work closely with Site Relationship Associates to facilitate site identification, development, and successful placement of clinical trials.
  • Assist in developing and maintaining site profiles to enable efficient trial matching.
  • Promote the capabilities of medical institutions within the network to sponsors and contract research organizations.
  • Communicate the benefits of partnering with the organization, including operational support and site readiness.
  • Identify investigators interested in participating in clinical research and support their engagement within the network.
  • Identify new clinical trial opportunities aligned with the capabilities of collaborating medical institutions.
  • Support the implementation of new clinical trials in collaboration with internal teams and medical institutions.
Desired Qualifications
  • Experience working with site networks or site-enabled research models.

About the company

P

PSI CRO

View
Website

PSI CRO is a global contract research organization that handles clinical trials for multiple therapeutic areas, with a focus on enrolling patients on schedule and delivering studies on time. Its services span feasibility assessments, trial planning, site selection, patient recruitment, and multi-continent trial execution across 50+ countries, backed by medical doctor resources dedicated to accurate timeline predictions. Unlike many CROs, PSI emphasizes predictable enrollment and on-time project delivery, aiming for high client satisfaction and repeat business through a pragmatic, no-nonsense approach. The company’s goal is to be regarded as the best CRO in the world by both clients and employees, achieved through reliable timelines, strong execution, and low staff turnover.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Switzerland

Founded

1995

Get referred to PSI CRO

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • SYNETIC cut site identification from six weeks to minutes by March 2026.
  • Beijing office, opened April 28, 2026, puts PSI closer to Chinese regulators.
  • Mexico, Toronto, and Japan expansions in 2025-2026 deepen coverage for Phase II-III trials.

What critics are saying

  • Parexel, IQVIA, and Medpace outspend PSI on technology, sales, and global program depth.
  • SYNETIC's AI promises face validation risk if recommendations miss enrolling sites in 2026.
  • One sponsor-program failure can dent PSI's repeat-business flywheel and pressure 2027 growth.

What makes PSI CRO unique

  • PSI CRO remains privately owned, independent, and reached 93% repeat business in 2025.
  • PSI CRO delivered 15% revenue growth in 2024 while keeping 9% global turnover.
  • PSI's 56-country footprint plus Beijing, Toronto, Mexico, and Japan offices shortens sponsor-to-site decisions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Paid Vacation
  • Flexible Work Hours
  • Hybrid Work Options
  • Remote Work Options
  • Wellness Program
  • Mental Health Support
  • Conference Attendance Budget
  • Professional Development Budget

Company News

Clinical Trial Vanguard
Sep 10th, 2026
PSI CRO to present agile models for emerging biotech at OCT New England.

PSI CRO to present agile models for emerging biotech at OCT New England. Ninety-three percent repeat business and 15% revenue growth in a single year puts PSI CRO in an unusual position for a mid-size CRO: sponsors keep coming back, which suggests the agility argument it plans to make at OCT New England next week is grounded in something operational rather than just a conference pitch. On October 27 at Encore Boston Harbor in Boston, Benjamin Raccanova, PSI's Head of Business Oversight, joins Stream C of the 18th Annual Outsourcing in Clinical Trials New England conference for a peer-driven session on how small and emerging biotech sponsors can hold onto operational control while scaling global programs. The pressure point is real: investor timelines, regulatory scrutiny, and the site-level complexity introduced by the FDA's 2024 final guidance on decentralized clinical trials all pull in different directions for a sponsor that doesn't have a 500-person clinical operations team to absorb the friction. The debate framing matters here. Raccanova's panel asks directly whether large CRO operating models are equipped to serve emerging biotech, which sets up a structural question that PSI has a commercial interest in answering a particular way, but also has data to back up. In 2024, 93% of PSI's studies enrolled on time or ahead of schedule. For a biotech sponsor burning cash against a runway, a slip in enrollment doesn't just delay a readout, it often triggers a bridge financing conversation. The session runs at 3:15 PM on October 27. Whether the peer discussion produces anything transferable beyond the room will depend on how many attending sponsors are willing to describe what broke in their last CRO relationship out loud. That candor, not the panel format itself, is what tends to make these conversations useful.

PSI CRO
Apr 28th, 2026
From Shanghai to Beijing: PSI CRO expands its footprint in China with a new Beijing office.

From Shanghai to Beijing: PSI CRO expands its footprint in China with a new Beijing office. Beijing, China - April 28, 2026 - PSI CRO, a Swiss-based global full-service contract research organization, today announced the opening of its second office in China, located in China World Tower B in Beijing's Chaoyang District. In 2019, PSI established its first China office in Shanghai, where the local team has steadily grown while supporting sponsors across the region. By adding a Beijing location, PSI brings its team closer to key drug regulatory authorities and leading research institutions. China is playing an increasingly important role in global clinical development, creating a growing need for strong local operational and regulatory support. PSI's presence in Beijing helps meet that need, combining local expertise with coordinated global teams to support clear decision-making and predictable, on-time delivery for sponsors. For PSI, the Beijing office represents a targeted investment to support clients where it matters most - close to regulators, close to investigator sites, and close to strategic partners.

PR Newswire
Mar 19th, 2026
PSI cuts clinical trial site selection from 6 weeks to minutes with AI agent on Arango platform

PSI CRO, a global clinical research organisation, has reduced clinical trial site identification from up to six weeks to minutes using SYNETIC, an AI knowledge engine powered by the Arango Contextual Data Platform. The system helps identify higher-performing trial sites and minimise costly non-enrolling institutions, which account for 30-40% of trial sites. Clinical trials can cost over $160 per minute operationally, and activating a trial site costs $30,000 or more. With 15% of sites never enrolling a single patient, failed recruitment can cost millions per study. SYNETIC unifies fragmented clinical research data into a single contextual layer, preserving relationships across investigators, institutions, protocols and historical outcomes. The platform provides explainable AI recommendations, including rationale, supporting evidence and confidence levels, enabling data-driven site selection in minutes rather than weeks.

PharmiWeb
Jan 7th, 2026
PSI CRO Strengthens Canadian Presence with New Toronto Office and Leadership Role

PSI CRO strengthens Canadian presence with new Toronto office and leadership role. PSI CRO has broadened its footprint in Canada by opening a new office in the Toronto area and naming an experienced industry leader to guide its operations there. The office, located in Mississauga, Ontario, builds on the company's established Canadian presence and commitment to clinical research excellence. PSI CRO has been active in Canada for over a decade, supporting complex clinical trials with a focus on dependable delivery and strong relationships with research sites. As part of this expansion, David Allen, MBA, has been appointed as Country Manager for Canada. Allen brings more than 30 years of experience in clinical research from both sponsor and CRO environments. In his new role, he will lead efforts to enhance the company's operational capabilities in the local market and ensure alignment with PSI's global standards for on-time trial execution. PSI's continued growth in North America reflects broader trends of increasing trial activity in the region, particularly for pivotal phase II and phase III studies where precision and efficiency are critical. The expanded Toronto operations aim to further support sponsors with rigorous trial planning and execution.

PSI CRO
Mar 13th, 2025
PSI CRO Appoints Sayaka Kaji as Country Manager Japan

TOKYO, 14 March 2025 - PSI CRO AG, a global Swiss-based clinical research organization (CRO), is pleased to announce the appointment of Sayaka Kaji as Country Manager for Japan.